1-(6-吡咯烷-1-基吡啶-3-基)乙酮 | 265107-45-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-(6-吡咯烷-1-基吡啶-3-基)乙酮
• 英文名称: 1-(6-(pyrrolidin-1-yl)pyridin-3-yl)ethan-1-one
• 英文别名: 1-(6-(Pyrrolidin-1-yl)pyridin-3-yl)ethanone；1-(6-pyrrolidin-1-ylpyridin-3-yl)ethanone
• CAS: 265107-45-7
• 化学式: C₁₁H₁₄N₂O
• 分子量: 190.245
• InChiKey: BEHACDSKKSIHEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-(6-吡咯烷-1-基吡啶-3-基)乙酮 在 tris formamide 、 ammonium acetate 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 5-(3-Bromo-phenyl)-7-(6-pyrrolidin-1-yl-pyridin-3-yl)-pyrido[2,3-d]pyrimidin-4-ylamine
  参考文献：
  名称：

  Pyridopyrimidine analogues as novel adenosine kinase inhibitors

  摘要：

  A novel series of pyridopyrimidine analogues 9 was identified as potent adenosine kinase inhibitors based on the SAR and computational studies. Substitution of the C7 position of the pyridopyrimidino core with C2 ' substituted pyridino moiety increased the in vivo potency and enhanced oral bioavailability of these adenosine kinase inhibitors. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00375-4
• 作为产物：
  描述：

  6-氯吡啶-3-羰酰氯 在 三乙胺 、 丙二酸二甲酯 、 magnesium chloride 作用下， 以 乙醇 为溶剂， 生成 1-(6-吡咯烷-1-基吡啶-3-基)乙酮
  参考文献：
  名称：

  Pyridopyrimidine analogues as novel adenosine kinase inhibitors

  摘要：

  A novel series of pyridopyrimidine analogues 9 was identified as potent adenosine kinase inhibitors based on the SAR and computational studies. Substitution of the C7 position of the pyridopyrimidino core with C2 ' substituted pyridino moiety increased the in vivo potency and enhanced oral bioavailability of these adenosine kinase inhibitors. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00375-4

文献信息

• [EN] PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF<br/>[FR] DÉRIVÉ DE PYRAZOLO[1,5-A]PYRIDINE, SON PROCÉDÉ DE PRÉPARATION ET COMPOSITION ET UTILISATION ASSOCIÉES<br/>[ZH] 一种吡唑并[1,5-a]吡啶类衍生物及其制备方法，组合物以及用途
  申请人：SHENZHEN JINGTAI TECH CO LTD

  公开号：WO2021213476A1

  公开（公告）日：2021-10-28

  本发明涉及一种吡唑并[1,5-a]吡啶类衍生物及其制备方法，组合物以及用途。具体地，本发明涉及式(I)化合物及其在用于治疗和/或预防与野生型、基因融合型(包括但不限于KIF5B、CCDC6和NCOA4)及突变型(包括但不限于G804、G810和M918)RET激酶相关的疾病，包括由RET激酶介导的疾病或病症。
• Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors
  作者：Andreas Blum、Dieter Dorsch、Nina Linde、Susanne Brandstetter、Hans-Peter Buchstaller、Michael Busch、Nina Glaser、Ulrich Grädler、Aaron Ruff、Carl Petersson、Hanno Schieferstein、Eva Sherbetjian、Christina Esdar

  DOI：10.1021/acs.jmedchem.2c00851

  日期：2023.2.23
• PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF
  申请人：SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD.

  公开号：US20230159523A1

  公开（公告）日：2023-05-25

  The present invention relates to a pyrazolo[1,5-a]pyridine derivative, a preparation method therefor, and a composition and a use thereof. Specifically, the present invention relates to the compound of formula (I) and the use thereof for the treatment and/or prevention of wild type, gene-fusion type (including but not limited to KIF5B, CCDC6 and NCOA4) and mutant type (including but not limited to V804, G810 and M918) RET kinases-related diseases, including diseases or conditions mediated by RET kinase.
• WO2023/84000
  申请人：——

  公开号：——

  公开（公告）日：——
• Pyridopyrimidine analogues as novel adenosine kinase inhibitors
  作者：Guo Zhu Zheng、Chih-Hung Lee、John K Pratt、Richard J Perner、Mei Qun Jiang、Arthur Gomtsyan、Mark A Matulenko、Yui Mao、John R Koenig、Ki H Kim、Steve Muchmore、Haixia Yu、Kathy Kohlhaas、Karen M Alexander、Steve McGaraughty、Katharine L Chu、Carol T Wismer、Joseph Mikusa、Michael F Jarvis、Kennan Marsh、Elizabeth A Kowaluk、Shripad S Bhagwat、Andrew O Stewart

  DOI：10.1016/s0960-894x(01)00375-4

  日期：2001.8

  A novel series of pyridopyrimidine analogues 9 was identified as potent adenosine kinase inhibitors based on the SAR and computational studies. Substitution of the C7 position of the pyridopyrimidino core with C2 ' substituted pyridino moiety increased the in vivo potency and enhanced oral bioavailability of these adenosine kinase inhibitors. (C) 2001 Elsevier Science Ltd. All rights reserved.